The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.
 
Joachim Aerts
Stock and Other Ownership Interests - amphera
Consulting or Advisory Role - Amphera; AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novocure
Research Funding - AstraZeneca (Inst); Nutricia (Inst)
Patents, Royalties, Other Intellectual Property - cdendritic cel based immunotherapy (Inst); combination immunotherapy (Inst); proteomics in nsclc (Inst)
(OPTIONAL) Uncompensated Relationships - IASLC; IMIG
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Carole Helissey
Honoraria - Accord Healthcare; Astellas Pharma; AstraZeneca; Bayer; BMSi; GlaxoSmithKline; Ipsen; Janssen; MSD Oncology; Pfizer; Viatris
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BMSi; Janssen; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Janssen; Pfizer
 
Federico Cappuzzo
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; bristol-myers; Lilly; MSD Oncology; Novocure; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Lilly; MSD Oncology; Novocure; pfizer; PharmaMar; Roche/Genentech; Sanofi; Takeda
Travel, Accommodations, Expenses - OSE Immunotherapeutics
 
Gilles Quere
No Relationships to Disclose
 
Dariusz Kowalski
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Johnson & Johnson/Janssen; Merck Serono; MSD; Pfizer; Roche/Genentech; Sanofi/Aventis; Takeda
 
Jose Carlos Benitez
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; AstraZeneca Spain; Daiichi Sankyo/Astra Zeneca; Roche; Sanofi; Takeda
 
Florian Guisier
Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Janssen; MSD; Pfizer; Roche; Sanofi; Takeda; Viatris
Consulting or Advisory Role - Amgen; AstraZeneca; BMS GmbH & Co. KG; MSD; Roche; Sanofi
Research Funding - Pfizer (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD; Takeda
 
Benjamin Besse
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Hedera Dx (Inst); Janssen (Inst); MSD (Inst); Roche (Inst); Sanofi/Aventis (Inst); Springer Healthcare Ltd (Inst)
Consulting or Advisory Role - Abbvie (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CureVac (Inst); Da voltera (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); F. Hoffmann LaRoche (Inst); Genmab (Inst); Immunocore (Inst); Janssen (Inst); Lilly (Inst); MSD Oncology (Inst); OSE Immunotherapeutics (Inst); Owkin (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst); Taiho Oncology (Inst); Turning Point Therapeutics (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Enliven Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); PharmaMar (Inst); Prelude Therapeutics (Inst); Roche/Genentech (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Shirish M. Gadgeel
Honoraria - Merck
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Daichii-Sanyko; Eisai; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Regeneron; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); Daichii Sanyko (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Dragonfly Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); I-Mab (Inst); Incyte (Inst); InventisBio (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Nektar (Inst); Numab (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); Ymabs Therapeutics Inc (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
Other Relationship - AstraZeneca
 
Thomas Wehler
Honoraria - Abbvie; Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
 
Ignacio Gil-Bazo
Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; MSD; Roche; Sanofi; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; MSD; Roche; Sanofi; Takeda
Research Funding - Merck (Inst)
 
Michael Jon Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Cem Gorgun
Employment - BioNTech SE
Stock and Other Ownership Interests - BioNTech SE
 
Ilhan Celik
Employment - BioNTech SE; Merck KGaA
Stock and Other Ownership Interests - BioNTech SE
Honoraria - BioNTech SE; Merck KGaA
Patents, Royalties, Other Intellectual Property - Merck KGaA
 
Marie Holst Mørch
Employment - Genmab
Stock and Other Ownership Interests - Genmab
 
Patricia Garrido Castro
Employment - Genmab
Stock and Other Ownership Interests - Genmab
 
Teng Jin Ong
Employment - Genmab
Stock and Other Ownership Interests - Genmab
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Peervoice; Pfizer; Roche; Sanofi; Takeda; Touch Oncology
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023